Philip S. Bernard

20.2k citations

91 papers · 11.2k indexed · 5 hit papers · h-index 36

Cancer Research top 0.1%
- Breast Cancer Treatment Studies 37
- Cancer Genomics and Diagnostics 17
Oncology top 0.2%
- HER2/EGFR in Cancer Research 18
- Cancer Cells and Metastasis 7
- Cancer Treatment and Pharmacology 6
Molecular Biology top 1%
- Molecular Biology Techniques and Applications 22
- Gene expression and cancer classification 19
Pathology and Forensic Medicine top 0.5%
Pulmonary and Respiratory Medicine top 1%
- Advanced Breast Cancer Therapies 7

Co-authors: Charles M. Perou Torsten O. Nielsen Joel S. Parker Matthew J. Ellis Maggie C.U. Cheang Samuel Leung Sherri R. Davies David Voduc
Cited by: Cancer Research Oncology Molecular Biology
Journals: Cell (1 paper)Nature Medicine (1 paper)Nature Genetics (1 paper)
Partner nations: United States Canada Spain

In The Last Decade

Philip S. Bernard

90 papers receiving 11.0k citations

Hit Papers

5 papers align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2011 Nature Medicine
2010 Clinical Cancer Research
2009 Journal of Clinical Oncology
2009 JNCI Journal of the National Cancer Institute
1994 Cell

Peers

Countries citing papers authored by Philip S. Bernard

Since Specialization

Citations

This map shows the geographic impact of Philip S. Bernard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip S. Bernard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip S. Bernard more than expected).

Fields of papers citing papers by Philip S. Bernard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip S. Bernard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip S. Bernard. The network helps show where Philip S. Bernard may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Philip S. Bernard, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Philip S. Bernard Line = papers co-authored together Philip S. Bernard links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Factors influencing opioid prescribing after tooth extraction The Journal of the American Dental Association ·Douglas R. Oyler,Marcia V. Rojas‐Ramirez,Aisaku Nakamura,Dana Quesinberry,Philip S. Bernard,Hilary L. Surratt,Craig S. Miller	2022	0
2	Multiparametric quantitative phase imaging for real-time, single cell, drug screening in breast cancer Communications Biology ·Edward R. Polanco,Tarek E. Moustafa,Andrew Butterfield,Sandra D. Scherer,Emilio Cortes-Sanchez,Tyler Bodily,Benjamin T. Spike,Bryan E. Welm,Philip S. Bernard,Thomas A. Zangle	2022	22
3	A Multigene Assay Determines Risk of Recurrence in Patients with Triple-Negative Breast Cancer Cancer Research ·Rachel L. Stewart,Katherine L. Updike,Rachel E. Factor,N. Lynn Henry,Kenneth M. Boucher,Philip S. Bernard,Katherine E. Varley	2019	35
4	Reparameterization of PAM50 Expression Identifies Novel Breast Tumor Dimensions and Leads to Discovery of a Genome-Wide Significant Breast Cancer Locus at 12q15 Cancer Epidemiology Biomarkers & Prevention ·Michael J. Madsen,Stacey Knight,Carol Sweeney,Rachel E. Factor,Mohamed E. Salama,Inge J. Stijleman,Venkatesh Rajamanickam,Bryan E. Welm,Sasi Arunachalam,Brandt Jones,Rakesh Rachamadugu,Kerry Rowe,Melissa H. Cessna,Alun Thomas,Lawrence H. Kushi,Bette J. Caan,Philip S. Bernard,Nicola J. Camp	2018	7
5	Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia Cancer Prevention Research ·Don A. Delker,Austin C. Wood,Angela K. Snow,N. Jewel Samadder,Wade S. Samowitz,Kajsa E. Affolter,Kenneth M. Boucher,Lisa M. Pappas,Inge J. Stijleman,Priyanka Kanth,Kathryn R. Byrne,Randall W. Burt,Philip S. Bernard,Deborah W. Neklason	2017	14
6	Body mass index, PAM50 subtype, recurrence, and survival among patients with nonmetastatic breast cancer Cancer ·Elizabeth M. Cespedes Feliciano,Marilyn L. Kwan,Lawrence H. Kushi,Wendy Y. Chen,Erin Weltzien,Adrienne Castillo,Carol Sweeney,Philip S. Bernard,Bette J. Caan	2017	39
7	Exercise and Prognosis on the Basis of Clinicopathologic and Molecular Features in Early-Stage Breast Cancer: The LACE and Pathways Studies Cancer Research ·Lee W. Jones,Marilyn L. Kwan,Erin Weltzien,Sarat Chandarlapaty,Barbara Sternfeld,Carol Sweeney,Philip S. Bernard,Adrienne Castillo,Laurel A. Habel,Candyce H. Kroenke,Bryan Langholz,Charles P. Queensberry,Chau T. Dang,Britta Weigelt,Lawrence H. Kushi,Bette J. Caan	2016	42
8	Consensus Analysis of Whole Transcriptome Profiles from Two Breast Cancer Patient Cohorts Reveals Long Non-Coding RNAs Associated with Intrinsic Subtype and the Tumour Microenvironment PLoS ONE ·James Bradford,Angela Cox,Philip S. Bernard,Nicola J. Camp	2016	19
9	Intrinsic Subtypes from PAM50 Gene Expression Assay in a Population-Based Breast Cancer Cohort: Differences by Age, Race, and Tumor Characteristics Cancer Epidemiology Biomarkers & Prevention ·Carol Sweeney,Philip S. Bernard,Rachel E. Factor,Marilyn L. Kwan,Laurel A. Habel,Charles P. Quesenberry,Kaylynn Shakespear,Erin Weltzien,Inge J. Stijleman,Carole Davis,Mark Ebbert,Adrienne Castillo,Lawrence H. Kushi,Bette J. Caan	2014	94
10	Prediction of Lung Cancer Histological Types by RT-qPCR Gene Expression in FFPE Specimens Journal of Molecular Diagnostics ·Matthew D. Wilkerson,Jason Schallheim,D. Neil Hayes,Patrick J. Roberts,Roy R. L. Bastien,Michael E. Mullins,Xiaoying Yin,C. Ryan Miller,Leigh B. Thorne,Katherine B. Geiersbach,Kenneth L. Muldrew,William K. Funkhouser,Cheng Fan,Michele C. Hayward,Steven R Bayer,Charles M. Perou,Philip S. Bernard	2013	16
11	A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen Clinical Cancer Research ·Stephen Chia,Vivien Bramwell,Dongsheng Tu,Lois E. Shepherd,Shan Jiang,Tammi L. Vickery,Elaine R. Mardis,Samuel Leung,Karen Ung,Kathleen I. Pritchard,Joel S. Parker,Philip S. Bernard,Charles M. Perou,Matthew J. Ellis,Torsten O. Nielsen	2012	220
12	Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial Clinical Cancer Research ·Maggie C.U. Cheang,K. David Voduc,Dongsheng Tu,Shan Jiang,Samuel Leung,Stephen Chia,Lois E. Shepherd,Mark N. Levine,Kathleen I. Pritchard,Sherri R. Davies,Inge J. Stijleman,Carole Davis,Mark Ebbert,Joel S. Parker,Matthew J. Ellis,Philip S. Bernard,Charles M. Perou,Torsten O. Nielsen	2012	105
13	Differential Pathogenesis of Lung Adenocarcinoma Subtypes Involving Sequence Mutations, Copy Number, Chromosomal Instability, and Methylation PLoS ONE ·Matthew D. Wilkerson,Xiaoying Yin,Vonn Walter,Ni Zhao,Christopher R. Cabanski,Michele C. Hayward,C. Ryan Miller,Mark A. Socinski,Alden M. Parsons,Leigh B. Thorne,Benjamin E. Haithcock,Nirmal K. Veeramachaneni,William K. Funkhouser,Scott H. Randell,Philip S. Bernard,Charles M. Perou,D. Neil Hayes	2012	192
14	Lung Squamous Cell Carcinoma mRNA Expression Subtypes Are Reproducible, Clinically Important, and Correspond to Normal Cell Types Clinical Cancer Research ·Matthew D. Wilkerson,Xiaoying Yin,Katherine A. Hoadley,Yufeng Liu,Michele C. Hayward,Christopher R. Cabanski,Kenneth L. Muldrew,C. Ryan Miller,Scott H. Randell,Mark A. Socinski,Alden M. Parsons,William K. Funkhouser,Carrie B. Lee,Patrick J. Roberts,Leigh B. Thorne,Philip S. Bernard,Charles M. Perou,D. Neil Hayes	2010	194
15	A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancerbreakdown → Clinical Cancer Research ·Torsten O. Nielsen,Joel S. Parker,Samuel Leung,D. Voduc,Mark Ebbert,Tammi L. Vickery,Sherri R. Davies,Jacqueline Snider,Inge J. Stijleman,Jerry P. Reed,Maggie C.U. Cheang,Elaine R. Mardis,Charles M. Perou,Philip S. Bernard,Matthew J. Ellis	2010	542
16	Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypesbreakdown → Journal of Clinical Oncology ·Joel S. Parker,Michael E. Mullins,Maggie C.U. Cheang,Samuel Leung,David Voduc,Tammi L. Vickery,Sherri R. Davies,Christiane Fauron,Xiaping He,Zhiyuan Hu,John F. Quackenbush,Inge J. Stijleman,Juan Palazzo,J. S. Marron,Andrew B. Nobel,Elaine R. Mardis,Torsten O. Nielsen,Matthew J. Ellis,Charles M. Perou,Philip S. Bernard	2009	3093
17	Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancerbreakdown → JNCI Journal of the National Cancer Institute ·Maggie C.U. Cheang,Stephen Chia,David Voduc,Dongxia Gao,Samuel Leung,Jacqueline Snider,Mark Watson,Sherri R. Davies,Philip S. Bernard,Joel S. Parker,Charles M. Perou,Matthew J. Ellis,Torsten O. Nielsen	2009	1641
18	Cytokeratin profiles of male breast cancers Histopathology ·Vincenzo Ciocca,Alessandro Bombonati,Zoran Gatalica,Marcello Di Pasquale,Anthony Milos,Alejandra Ruiz-Orrico,Donna Dreher,Nathalie Folch,Federico A. Monzon,Giuseppe Santeusanio,Charles M. Perou,Philip S. Bernard,Juan Palazzo	2006	22
19	Molecular classification of melanoma using real‐time quantitative reverse transcriptase‐polymerase chain reaction Cancer ·Tracey Lewis,John Elder Robison,Roy R. L. Bastien,Brett Milash,Kenneth M. Boucher,Wolfram E. Samlowski,Sancy A. Leachman,R. Dirk Noyes,Carl T. Wittwer,Laurent Perreard,Philip S. Bernard	2005	49
20	Rapid F508del and F508C Assay Using Fluorescent Hybridization Probes Genetic Testing ·Cameron N. Gundry,Philip S. Bernard,Mark G. Herrmann,GUNDRUN H. REED,Carl T. Wittwer	1999	39

About Philip S. Bernard

Philip S. Bernard is a scholar working on Cancer Research, Oncology and Pathology and Forensic Medicine, having authored 91 papers that have together received 11.2k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (37 papers), Molecular Biology Techniques and Applications (22 papers), Gene expression and cancer classification (19 papers), HER2/EGFR in Cancer Research (18 papers), Cancer Genomics and Diagnostics (17 papers), Cancer Cells and Metastasis (7 papers), Advanced Breast Cancer Therapies (7 papers) and Cancer Treatment and Pharmacology (6 papers). The work is most often cited by research in Cancer Research (5.6k citations), Oncology (5.2k citations) and Molecular Biology (5.0k citations). Philip S. Bernard has collaborated with scholars based in United States, Canada and Spain. Frequent co-authors include Charles M. Perou, Torsten O. Nielsen, Joel S. Parker, Matthew J. Ellis, Maggie C.U. Cheang, Samuel Leung, Sherri R. Davies, David Voduc, Inge J. Stijleman and Tammi L. Vickery. Their work appears in journals such as Cell, Nature Medicine and Nature Genetics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact